tetano
Editor, Senior Moderator
Sci Rep
. 2022 Nov 21;12(1):20048.
doi: 10.1038/s41598-022-23922-2.
Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality
Alisia Madè[SUP] 1 [/SUP], Simona Greco[SUP] 1 [/SUP], Melanie Vausort[SUP] 2 [/SUP], Marios Miliotis[SUP] 3 4 [/SUP], Eric Schordan[SUP] 5 [/SUP], Shounak Baksi[SUP] 2 [/SUP], Lu Zhang[SUP] 6 [/SUP], Ekaterina Baryshnikova[SUP] 7 [/SUP], Marco Ranucci[SUP] 7 [/SUP], Rosanna Cardani[SUP] 8 [/SUP], Guy Fagherazzi[SUP] 9 [/SUP], Markus Ollert[SUP] 10 11 [/SUP], Spyros Tastsoglou[SUP] 3 4 [/SUP], Giannis Vatsellas[SUP] 12 [/SUP], Artemis Hatzigeorgiou[SUP] 3 4 [/SUP], Hüseyin Firat[SUP] 5 [/SUP], Yvan Devaux[SUP] 13 [/SUP], Fabio Martelli[SUP] 14 [/SUP]
Affiliations
Abstract
Coronavirus disease-2019 (COVID-19) can be asymptomatic or lead to a wide symptom spectrum, including multi-organ damage and death. Here, we explored the potential of microRNAs in delineating patient condition and predicting clinical outcome. Plasma microRNA profiling of hospitalized COVID-19 patients showed that miR-144-3p was dynamically regulated in response to COVID-19. Thus, we further investigated the biomarker potential of miR-144-3p measured at admission in 179 COVID-19 patients and 29 healthy controls recruited in three centers. In hospitalized patients, circulating miR-144-3p levels discriminated between non-critical and critical illness (AUC[SUB]miR-144-3p[/SUB] = 0.71; p = 0.0006), acting also as mortality predictor (AUC[SUB]miR-144-3p[/SUB] = 0.67; p = 0.004). In non-hospitalized patients, plasma miR-144-3p levels discriminated mild from moderate disease (AUC[SUB]miR-144-3p[/SUB] = 0.67; p = 0.03). Uncontrolled release of pro-inflammatory cytokines can lead to clinical deterioration. Thus, we explored the added value of a miR-144/cytokine combined analysis in the assessment of hospitalized COVID-19 patients. A miR-144-3p/Epidermal Growth Factor (EGF) combined score discriminated between non-critical and critical hospitalized patients (AUC[SUB]miR-144-3p/EGF[/SUB] = 0.81; p < 0.0001); moreover, a miR-144-3p/Interleukin-10 (IL-10) score discriminated survivors from nonsurvivors (AUC[SUB]miR-144-3p/IL-10[/SUB] = 0.83; p < 0.0001). In conclusion, circulating miR-144-3p, possibly in combination with IL-10 or EGF, emerges as a noninvasive tool for early risk-based stratification and mortality prediction in COVID-19.
. 2022 Nov 21;12(1):20048.
doi: 10.1038/s41598-022-23922-2.
Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality
Alisia Madè[SUP] 1 [/SUP], Simona Greco[SUP] 1 [/SUP], Melanie Vausort[SUP] 2 [/SUP], Marios Miliotis[SUP] 3 4 [/SUP], Eric Schordan[SUP] 5 [/SUP], Shounak Baksi[SUP] 2 [/SUP], Lu Zhang[SUP] 6 [/SUP], Ekaterina Baryshnikova[SUP] 7 [/SUP], Marco Ranucci[SUP] 7 [/SUP], Rosanna Cardani[SUP] 8 [/SUP], Guy Fagherazzi[SUP] 9 [/SUP], Markus Ollert[SUP] 10 11 [/SUP], Spyros Tastsoglou[SUP] 3 4 [/SUP], Giannis Vatsellas[SUP] 12 [/SUP], Artemis Hatzigeorgiou[SUP] 3 4 [/SUP], Hüseyin Firat[SUP] 5 [/SUP], Yvan Devaux[SUP] 13 [/SUP], Fabio Martelli[SUP] 14 [/SUP]
Affiliations
- PMID: 36414650
- DOI: 10.1038/s41598-022-23922-2
Abstract
Coronavirus disease-2019 (COVID-19) can be asymptomatic or lead to a wide symptom spectrum, including multi-organ damage and death. Here, we explored the potential of microRNAs in delineating patient condition and predicting clinical outcome. Plasma microRNA profiling of hospitalized COVID-19 patients showed that miR-144-3p was dynamically regulated in response to COVID-19. Thus, we further investigated the biomarker potential of miR-144-3p measured at admission in 179 COVID-19 patients and 29 healthy controls recruited in three centers. In hospitalized patients, circulating miR-144-3p levels discriminated between non-critical and critical illness (AUC[SUB]miR-144-3p[/SUB] = 0.71; p = 0.0006), acting also as mortality predictor (AUC[SUB]miR-144-3p[/SUB] = 0.67; p = 0.004). In non-hospitalized patients, plasma miR-144-3p levels discriminated mild from moderate disease (AUC[SUB]miR-144-3p[/SUB] = 0.67; p = 0.03). Uncontrolled release of pro-inflammatory cytokines can lead to clinical deterioration. Thus, we explored the added value of a miR-144/cytokine combined analysis in the assessment of hospitalized COVID-19 patients. A miR-144-3p/Epidermal Growth Factor (EGF) combined score discriminated between non-critical and critical hospitalized patients (AUC[SUB]miR-144-3p/EGF[/SUB] = 0.81; p < 0.0001); moreover, a miR-144-3p/Interleukin-10 (IL-10) score discriminated survivors from nonsurvivors (AUC[SUB]miR-144-3p/IL-10[/SUB] = 0.83; p < 0.0001). In conclusion, circulating miR-144-3p, possibly in combination with IL-10 or EGF, emerges as a noninvasive tool for early risk-based stratification and mortality prediction in COVID-19.